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Group B Streptococcus (GBS) is increasingly causing invasive infections in non-pregnant
adults. Elderly patients and those with comorbidities are at increased risk. On the
basis of previous studies focusing on neonatal infections, penicillin plus gentamicin is
recommended for infective endocarditis (IE) and periprosthetic joint infections (PJI) in
adults. The purpose of this study was to investigate whether a synergism with penicillin
and gentamicin is present in GBS isolates that caused IE and PJI. We used 5 GBS
isolates, two clinical strains and three control strains, including one displaying high-level
gentamicin resistance (HLGR). The results from the checkerboard and time-kill assays
(TKAs) were compared. For TKAs, antibiotic concentrations for penicillin were 0.048
and 0.2 mg/L, and for gentamicin 4 mg/L or 12.5 mg/L. In the checkerboard assay,
the median fractional inhibitory concentration indices (FICIs) of all isolates indicated
indifference. TKAs for all isolates failed to demonstrate synergism with penicillin 0.048
or 0.2 mg/L, irrespective of gentamicin concentrations used. Rapid killing was seen with
penicillin 0.048 mg/L plus either 4 mg/L or 12.5 mg/L gentamicin, from 2 h up to 8 h
hours after antibiotic exposure. TKAs with penicillin 0.2 mg/L decreased the starting
inoculum below the limit of quantification within 4–6 h, irrespective of the addition of
gentamicin. Fast killing was seen with penicillin 0.2 mg/L plus 12.5 mg/L gentamicin
within the first 2 h. Our in vitro results indicate that the addition of gentamicin to penicillin
contributes to faster killing at low penicillin concentrations, but only within the first few
hours. Twenty-four hours after antibiotic exposure, PEN alone was bactericidal and
synergism was not seen.
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INTRODUCTION
Streptococcus agalactiae (group B Streptococcus [GBS]) is considered a leading cause of morbidity
and mortality in neonates and pregnant women. Recommendations for diagnosing maternal GBS
colonization and administering intrapartum antimicrobial prophylaxis have led to a significant
decrease in these infections (Schrag et al., 2002). Nonetheless, the rate of invasive GBS disease
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in non-pregnant adults continues to climb (Phares et al., 2008).
Elderly persons and those with underlying diseases – two
expanding segments of the population – are at increased risk
(Skoff et al., 2009). This epidemiological shift is associated with
uncertainty in clinical management. Because treatment concepts
in adults are not established, those used for neonates – i.e., the
combination of β-lactams plus an aminoglycoside (Polin, 2012) –
are transferred to adults. For example, some experts advocate this
combination therapy for at least the first 2 weeks of treatment for
infective endocarditis (IE) (Baddour, 1998; Westling et al., 2007)
and periprosthetic joint infection (PJI) (Zimmerli et al., 2004).
These recommendations are based on a postulated synergistic
effect with penicillin (PEN) and gentamicin (GEN) observed in
in vitro studies (Cooper et al., 1979; Baker et al., 1981; Swingle
et al., 1985). However, adults, especially elderly persons, are more
prone to develop side effects caused by aminoglycosides (e.g.,
nephrotoxicity and ototoxicity) than are neonates (Gonzalez and
Spencer, 1998). Here, we evaluated the synergistic effect of PEN
and GEN, using contemporary clinical isolates obtained from
adults with IE and PJI, and the same antimicrobial products that
are administered in clinical practice.
MATERIALS AND METHODS
Bacterial Isolates
Five GBS isolates were used for this study. All isolates were
characterized by serotyping (by agglutination [Strep-B-Latex,
Statens Serum Institut, Copenhagen, Denmark] and PCR [Imperi
et al., 2010]) and multilocus sequence typing (Jones et al., 2003).
Two were obtained from patients with PJI and IE (designated as
GBS-PJI [BE07-1b] and GBS-IE [BE05-1]). Both were serotype
Ib, and sequence type 8. We used three control strains: NEM316
(serotype III, sequence type 23), a strain frequently used in
laboratory experiments (Glaser et al., 2002), a colonizing isolate
representing a non-virulent strain (designated as GBS-Col [BE12-
2], serotype III, sequence type 188), and a previously published
high-level GEN-resistant (designated as GBS-HLGR [BSU1203],
serotype V, sequence type 7) GBS (Sendi et al., 2016).
Antibiotics and Concentrations Used
PEN (benzylpenicillin-sodium, Grünenthal Pharma, Mitlödi,
Switzerland) and GEN (Hexal AG, Holzkirchen, Germany)
were supplied from the clinical pharmacy of the University
Hospital (Bern, Switzerland). In time-kill assays (TKAs), PEN
concentrations were 0.048 mg/L and 0.2 mg/L, and GEN
concentrations were 4 mg/L and 12.5 mg/L. The rationale to
use 0.048 mg/L and 0.2 mg/L PEN was based on (i) the
setting in previous studies using approximately 1 × MIC
(Baker et al., 1981) and (ii) a theoretical extrapolation of
PEN concentrations in extravascular compartments. Assuming
a penetration proportion of 10–20% (Landersdorfer et al.,
2009), and a serum trough level of 3 mg/L (Plaut et al.,
1969; Geddes and Gould, 2010), PEN bone concentration is
not expected to fall below 0.2 mg/L when intravenous (i.v.)
treatment for osteomyelitis or PJI is administered (Zimmerli
et al., 2004). The rational to use GEN concentrations of 4 mg/L
and 12.5 mg/L is based on GEN peak concentrations found in
adults when using i.v., 1 mg/kg or 3 mg/kg (Nicolau et al., 1995).
PEN concentrations were diluted from original vials (1 Mio
IU), and the concentrations were confirmed via measurements
with a UV high-performance liquid chromatography (HPLC)
method. GEN concentrations were diluted from original vials
(80 mg/2 mL), and the concentrations were confirmed via
measurements with a fluorescence polarization immunoassay
(COBAS INTEGRA Gentamicin, Roche Diagnostics, Mannheim,
Germany). A difference of up to 10% between calculated (i.e.,
diluted) and measured antimicrobial concentration was allowed
in order to proceed with the experiments.
MIC
Antibiotic susceptibilities for PEN were tested with Etest
(Biomérieux, Marcy l’Etoile, France) according to the
manufacturer’s protocol, and with microbroth dilution according
to protocol (Amsterdam, 2005; Hindler and Tamashiro, 2010).
Antibiotic susceptibilities for GEN were tested with microbroth
dilution according to protocol (Amsterdam, 2005; Hindler and
Tamashiro, 2010). All isolates were tested three or more times.
Checkerboard Assays
Checkerboard assays were performed as described previously
(Pillai et al., 2005; Moody, 2010). In brief, 96-well plates
were prepared by serially twofold diluting the first antibiotic
(PEN) along the horizontal axis (left [highest concentration;
0.16 mg/L] to right [lowest concertation; 0.0004 mg/L]), and
the second antibiotic (GEN) along the vertical axis (top [highest
concertation; 250 mg/L] to bottom [lowest concentration;
1.95 mg/L]) in cation-adjusted Mueller Hinton broth (Bacto,
Becton, Dickinson and Company, Sparks, MD, USA). Thus, the
highest concentration of both antibiotics was in top left well and
the lowest of both antibiotics in the bottom right well of the 96-
well plate. McFarland 0.5 suspension was prepared and diluted to
obtain a final GBS concentration of 3× 105 to 5× 105 CFU/mL in
each well (Hindler and Tamashiro, 2010). Plates were incubated
at 37◦C in 5% CO2 for 24 h and read out with a microplate reader
(Varioskan, Thermo Scientific, Reinach, Switzerland). All assays
were repeated at least three times.
Time-Kill Assays (TKAs)
Time-kill assays were performed according to a previous protocol
(Amsterdam, 2005; Moody and Knapp, 2010). Various test
conditions were evaluated to determine those that were most
stable for GBS (Ruppen and Sendi, 2015). In brief, 1 × 105 to
106 CFU/mL mid-log-phase GBS were incubated in Todd Hewitt
broth (Bacto, Becton, Dickinson and Company, Sparks, MD,
USA) with either PEN monotherapy, GEN monotherapy, or PEN
plus GEN in a total volume of 5 mL at 37◦C in 5% CO2. Samples
of 0.1 mL were obtained at multiple time points up to 24 h after
antibiotic exposure, and then plated on Columbia sheep blood
agar for colony counting. The lower limit of quantification (LOQ)
was defined as 200 CFU/mL and the upper as 3500 CFU/mL
[i.e., 20 and 350 CFU, respectively, per plate (Sutton, 2011)].
Assays were repeated multiple times and always performed with
triplicates.
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Synergism Assays and Definition
In killing assays, synergy was defined as a ≥100-fold (≥2 log)
increase in killing at 24 h (as measured by colony counts
[CFU/mL]) with the combination therapy in comparison with
the most active single drug (Pillai et al., 2005; Moody and Knapp,
2010). A bactericidal effect was defined as killing of ≥99.9%
[i.e., (≥3 log) of the organism within 24 h (Pankey and Sabath,
2004)]. In checkerboard assays, for each strain and for each
combination interaction the fractional inhibitory concentration
(FIC) of PEN or GEN was calculated (FIC of PEN=MIC of PEN
in combination/MIC of PEN alone; FIC of GEN =MIC of GEN
in combination/MIC of GEN alone). Then, the FICI (FIC index)
was calculated by the summation of both FIC [FICI = FIC of
PEN + FIC of GEN (Hindler and Tamashiro, 2010)]. Synergism
was defined when FICI resulted in ≤0.5. In the view that this
method is a mathematical restatement of an isobologram, “0.5”
theoretically reflects the point with one half of the MIC of
PEN and one half of the MIC of GEN (Pillai et al., 2005;
Moody, 2010). Indifference was defined when the summation
of FICI resulted between 0.5< and ≤4, and antagonism when
FICI was >4 (Hindler and Tamashiro, 2010)). We did not use
the categorization of ‘additive’ because of inherent variability in
results derived from the twofold dilution scheme, as described
previously (Pillai et al., 2005).
RESULTS
MICs, Checkerboard Assays and FICI
Results
The results from MICs, checkerboard assays and FICIs for all
isolates are shown in Table 1. The MIC results are shown as
median and range. As expected, all isolates were susceptible to
PEN. The MICs were within the same result range when tested
with microbroth dilution and Etests. Considering the range of
all performed measurements, and a precision error associated
with measuring an MIC (i.e., plus or minus one 2-fold dilution)
(Turnidge and Paterson, 2007), we determined 0.048 mg/L as
concentration to use for these experiments. It was within the
range of 1 × MIC for all isolates. The MICs for gentamicin
cannot be interpreted (except for the presence of HLGR), because
no standard criteria for susceptibility testing are available. The
results from checkerboard assays indicated indifference for all
isolates, with the lowest FICI for NEM316, ranging from 0.7 to
1. The vast majority of FICI calculations for the other strains
resulted in >1 (Table 1).
Time-Kill Assays
PEN with 0.048 mg/L
In all isolates, bactericidal killing of GBS at 24 h was observed
with PEN monotherapy (Figure 1). In isolates obtained from
patients with PJI and IE, the killing was better with PEN plus
GEN 4 mg/L or PEN plus GEN 12.5 mg/L at 4, 6, and 8 h
(Figures 1A,B). In NEM316 and the colonizing isolate, killing
curves of PEN monotherapy and PEN plus GEN 4 mg/L were
similar. Though, the killing was better in NEM316 with PEN plus
GEN 12.5 mg/L at 4, 6, and 8 h (Figure 1C).
PEN with 0.2 mg/L
In all isolates but the GBS-Col, killing of GBS decreased the
starting inoculum below the LOQ within 4–6 h, irrespective of
the addition of GEN (Figure 2). In all but the GBS-HLGR isolate,
PEN plus 12.5 mg/L GEN showed this killing pattern within
2 h. TKAs with GEN monotherapy showed persistent bacterial
growth at 24 h (Supplementary Figure S1).
Synergism
At 24 h after antibiotic exposure, PEN monotherapy proved to
be bactericidal. When synergism was tested with checkerboard
assays, none of isolates revealed a FICI value indicating a
synergistic effect. Similarly, in TKAs no significant difference
was seen in colony counts at 24 h when PEN monotherapy
was compared with PEN plus GEN combination therapy.
Hence, the lack of synergism correlated in the two laboratory
methods.
DISCUSSION
Rates of invasive GBS disease in non-pregnant adults continue
to climb. Hence, clinicians are faced with the challenge of
transferring therapeutic knowledge from neonatal sepsis to
infections in adults. Other groups previously reported synergism
with PEN plus GEN toward GBS (Overturf et al., 1977; Cooper
et al., 1979; Baker et al., 1981; Swingle et al., 1985). We used two
different methods with isolates obtained from adults and could
TABLE 1 | Antimicrobial susceptibilities (mg/L) and FICIs.
Isolate MIC (PEN)MB MIC (PEN)E MIC (GEN)MB FICIsMB
GBS-PJI 0.03 (0.016–0.04) 0.064 (0.047–0.064) 23.4 (15.6–31.25) 1.4 (0.9–1.5)
GBS-IE 0.04 (0.016–0.04) 0.064 (0.032–0.064) 15.6 (7.8–15.6) 1.4 (0.8–2.3)
NEM316 0.04 (0.032–0.04) 0.064 (0.047–0.064) 15.6 (7.8–15.6) 0.8 (0.7–1)
GBS-Col 0.02 (0.016–0.04) 0.064 (0.047–0.064) 7.8 (7.8–15.6) 2 (1.5–2)
GBS-HLGR 0.04 (0.016–0.04) 0.047 (0.047–0.047) >1024 2 (2–2)
All measurements were repeated three or more times. MIC results are presented as median and range of results in parenthesis. E, Etest; MB, microbroth dilution; PEN,
penicillin; GEN, gentamicin; FICI, fractional inhibitory concentration index; GBS-PJI, group B Streptococcus isolated from a periprosthetic joint infection; GBS-IE, group
B Streptococcus isolated from infective endocarditis; GBS-Col, group B Streptococcus isolated from colonized women; GBS-HLGR, group B Streptococcus displaying
high level gentamicin resistance.
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FIGURE 1 | Time-kill assays with penicillin 0.048 mg/L. Results are displayed as mean ± standard error of the mean (SEM). PEN 0.048 mg/L monotherapy ( ),
PEN 0.048 mg/L plus GEN 4 mg/L () and PEN 0.048 mg/L plus GEN 12.5 mg/L (N). Isolates: GBS-PJI, periprosthetic joint infection (A); GBS-IE, infective
endocarditis (B); NEM316, neonatal sepsis (C); GBS-Col, colonization isolate (D); GBS-HLGR, high-level gentamicin resistance (E). Growth controls of all isolates
(F). LOQ: lower limit of quantification.
not confirm these results. The following arguments may explain
the differences between the results of previous studies and those
provided in the present study.
The definitions and methods used for synergism vary and
all have limitations. This again points toward the difficulty to
transfer synergy assay results from the laboratory to patient
treatment concepts. The two commonly used laboratory methods
to evaluate synergism are checkerboard assays and TKAs over
a predetermined time interval, as used in the present study.
Although the checkerboard method has been reported to have
reproducibility problems (Rand et al., 1993), the range of results
in our multiple repeated assays was small (Table 1). Because
the effect of the antibiotic combination in the checkerboard
method can be observed at only a single time point, in the
TKAs, we used the advantage of measuring the colony counts
at various time points up to 24 h after antibiotic exposure. With
the last time point, we were able to show a parallel in the results
of both methods. In contrast to previous analyses showing a
lack of correlation between FICIs and killing curves (Hallander
et al., 1982; Bayer and Morrison, 1984; Swingle et al., 1985), our
results for both methods were congruent in that they showed no
synergistic response.
Some investigators use the first 4–8 h after exposure to an
antimicrobial agent or a combination of agents to compare
differences in colony counts (Cooper et al., 1979). In our view,
this method reflects rapid killing, as shown in our experiments
with PEN 0.048 mg/L plus GEN 4 mg/L or 12.5 mg/L (Figure 1),
or PEN 0.2 m/L plus GEN 12.5 mg/L (Figure 2). These
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FIGURE 2 | Time-kill assays with penicillin 0.2 mg/L. Results are displayed as mean ± standard error of the mean (SEM). PEN 0.2 mg/L monotherapy ( ), PEN
0.2 mg/L plus GEN 4 mg/L (), PEN 0.2 mg/L plus GEN 12.5 mg/L (N). Isolates: GBS-PJI, periprosthetic joint infection (A); GBS-IE, infective endocarditis (B);
NEM316, neonatal sepsis (C); GBS-Col, colonization isolate (D); GBS-HLGR, high-level gentamicin resistance (E). Growth controls of all isolates (F). LOQ: lower
limit of quantification.
results may be helpful to describe potentially beneficial clinical
interactions in the very early stage of treatment. Though, they
are difficult to standardize (e.g., dynamic of bacterial replication
can be variable at different time points). Therefore, differences
in colony count measurements at 4 h to 8 h are commonly not
used for the definition of synergism (Pillai et al., 2005; Moody
and Knapp, 2010). Other means to determine synergy may be
more accurate from today’s perspective (e.g., molecular synergy)
(McCafferty et al., 1999).
As a consequence of lack of synergism, these results
theoretically argue against prolonged combination therapy. The
clinical relevance of the laboratory phenomenon “synergism”
is difficult to estimate. The bacterial inoculum in time-kill
experiments is up to 100,000 times higher than that found in
human sepsis (Yagupsky and Nolte, 1990; Puttaswamy et al.,
2011). Also, the antibiotic concentrations found in humans
treated for bacteremia are significantly higher than the ones used
in TKAs. Ten minutes after completion of i.v., administration of 5
million U PEN, the mean serum concentration is 273 mg/L (Plaut
et al., 1969; Geddes and Gould, 2010). This corresponds to more
than 5,500 times the PEN concentration used in this study. In
addition, in severe GBS disease (e.g., IE, PJI), PEN is commonly
administered i.v., every 4–6 h (e.g., 18–24 million U/day i.v., in
six doses) (Zimmerli et al., 2004; Habib et al., 2009). In vivo PEN
concentrations decrease in human serum over time. Nonetheless,
prior to administration of the next dose, they rarely fall to those
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levels used in experimental settings. For example, 4 hours after
completion of i.v., administration of 5 million IU PEN, the mean
serum concentration is 3 mg/L (i.e., >60 times higher than the
concentration used in this study) (Plaut et al., 1969; Geddes and
Gould, 2010).
In our study, we saw rapid killing of GBS with 0.2 mg/L
PEN monotherapy. The killing rate was fastened by 2–4 h
when GEN 12.5 mg/L was added. There are no standard
concentrations at which antibiotics are tested for synergism. The
results with PEN concentrations in the range of 1 × MIC have
to be interpreted with caution because of the following reasons.
Experiments depend on the precise inoculum (Brook, 1989), the
exact determination of MIC, and the antibiotic concentration.
In our isolates, PEN MICs were determined by using two
different methods and multiple measurements. Moreover, the
antibiotic concentrations used were based on calculated dilutions,
but confirmed with measurements via fluorescence polarization
immunoassay and HPLC.
Various GEN concentrations and products have been used in
previous in vitro experiments, ranging from 0.5 mg/L to 13 mg/L
(Overturf et al., 1977; Cooper et al., 1979; Baker et al., 1981; Kim
and Anthony, 1981; Kim, 1987). Since GEN alone in non-toxic
systemic concentrations has little or no effect on GBS, the optimal
setting for testing synergism in TKAs is unknown. The antibiotic
concentrations of combinations used in in vitro settings are often
not physiological, because PEN is far below achievable serum
concentrations, although GEN is within the expected range. On
the other hand, higher in vitro PEN concentrations diminish
the visible GEN effect, and lower GEN concentrations have no
effect. The benefit of rapid killing within the first few hours when
adding GEN is difficult to interpret for clinical practice, because
of the low PEN concentrations used in this study (0.048 mg/L
and 0.2 mg/L). Considering the high PEN concentrations and the
low inoculum during bacteremia found in humans [e.g., ≤102
cfu/mL; (Yagupsky and Nolte, 1990; Puttaswamy et al., 2011)],
we hypothesize no beneficial clinical effect for planktonic bacteria
when GEN is added. A clinical trial is required to confirm or
reject this hypothesis.
The stability of our results is supported by the small variation
seen in multiple assays, comparing TKA results under various
conditions (Ruppen and Sendi, 2015) and the use of a HLGR GBS
isolate (Sendi et al., 2016).
Another reason for the differences in results found in our
study in comparison to previous investigations might be the PEN
product. The efficacy of a drug depends largely on the purity of
the active ingredient. It is conceivable that the manufacturing
process has improved over the decades (van der Beek and Roels,
1984; Penalva et al., 1998). Here, we used PEN products that are
administered to patients. However, because we cannot compare
older products with the ones used in this study, this statement
remains speculative.
We cannot uncritically extrapolate our findings for five isolates
to other GBS isolates. Nonetheless, the isolates were obtained
from two patients with invasive diseases in which the addition of
gentamicin is recommended (IE and PJI). In addition, we used
3 control isolates [two of them previously investigated (Glaser
et al., 2002; Sendi et al., 2016)]. The number of isolates used in
our study is small. Though, analyzes were performed at multiple
time points within the first 8 h for every single isolates. In our
view, this information is important in the light that – in clinical
practice – PEN is administered every 4–6 h.
CONCLUSION
Our study reinvestigated the synergism of PEN plus GEN with
two common laboratory methods, clinical isolates in mid-log
growth phase and antimicrobial products administered in clinical
practice. Synergism according to definition was not observed
with either of the methods. In view of the potential nephrotoxicity
of aminoglycosides and the increasing elderly population at risk
for invasive GBS disease, our findings may have implications for
the decision to administer or withhold aminoglycosides.
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